Novo Nordisk A/S
CSE:NOVO B

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
CSE:NOVO B
Watchlist
Price: 398 DKK -5.52%
Market Cap: 1.8T DKK

Intrinsic Value

The intrinsic value of one NOVO B stock under the Base Case scenario is 724.86 DKK. Compared to the current market price of 398 DKK, Novo Nordisk A/S is Undervalued by 45%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

NOVO B Intrinsic Value
724.86 DKK
Undervaluation 45%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Novo Nordisk A/S

NOVO B
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for NOVO B cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Novo Nordisk A/S
CSE:NOVO B
DK
Pharmaceuticals
Market Cap
1.8T DKK
IPO
May 17, 1974
DK
Pharmaceuticals
Market Cap
1.8T DKK
IPO
May 17, 1974
Price
krfalse
EPS
krfalse
Company Overview
Loading...
Business Segments
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about NOVO B?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Novo Nordisk A/S
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Novo Nordisk A/S

Current Assets 160.9B
Cash & Short-Term Investments 26.3B
Receivables 87.4B
Other Current Assets 47.2B
Non-Current Assets 304.9B
Long-Term Investments 2.7B
PP&E 162.5B
Intangibles 111.1B
Other Non-Current Assets 28.6B
Efficiency

Free Cash Flow Analysis
Novo Nordisk A/S

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Novo Nordisk A/S

Revenue
290.4B DKK
Cost of Revenue
-43.6B DKK
Gross Profit
246.8B DKK
Operating Expenses
-107.9B DKK
Operating Income
138.9B DKK
Other Expenses
-37.9B DKK
Net Income
101B DKK
Fundamental Scores

NOVO B Profitability Score
Profitability Due Diligence

Novo Nordisk A/S's profitability score is 84/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Free Cash Flow
Exceptional 3-Year Average ROIC
Positive Gross Profit
84/100
Profitability
Score

Novo Nordisk A/S's profitability score is 84/100. The higher the profitability score, the more profitable the company is.

NOVO B Solvency Score
Solvency Due Diligence

Novo Nordisk A/S's solvency score is 70/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Low D/E
Long-Term Solvency
70/100
Solvency
Score

Novo Nordisk A/S's solvency score is 70/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NOVO B Price Targets Summary
Novo Nordisk A/S

There are no price targets for NOVO B.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for NOVO B is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

NOVO B News

Other Videos
What is the Intrinsic Value of one NOVO B stock?

The intrinsic value of one NOVO B stock under the Base Case scenario is 724.86 DKK.

Is NOVO B stock undervalued or overvalued?

Compared to the current market price of 398 DKK, Novo Nordisk A/S is Undervalued by 45%.

Back to Top